1. Home
  2. FRMI vs GKOS Comparison

FRMI vs GKOS Comparison

Compare FRMI & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FRMI

Fermi Inc.

N/A

Current Price

$7.51

Market Cap

6.0B

Sector

Real Estate

ML Signal

N/A

Logo Glaukos Corporation

GKOS

Glaukos Corporation

N/A

Current Price

$105.34

Market Cap

6.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FRMI
GKOS
Founded
2025
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Medical/Dental Instruments
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.0B
6.0B
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
FRMI
GKOS
Price
$7.51
$105.34
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
14
Target Price
$29.50
$133.07
AVG Volume (30 Days)
6.7M
557.1K
Earning Date
04-30-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$507,442,000.00
Revenue This Year
N/A
$23.34
Revenue Next Year
$3,427.92
$27.46
P/E Ratio
N/A
N/A
Revenue Growth
N/A
32.33
52 Week Low
$7.17
$73.16
52 Week High
$32.39
$130.23

Technical Indicators

Market Signals
Indicator
FRMI
GKOS
Relative Strength Index (RSI) 41.54 45.95
Support Level $7.36 $104.72
Resistance Level $10.57 $113.50
Average True Range (ATR) 0.59 4.04
MACD -0.10 0.15
Stochastic Oscillator 28.86 51.08

Price Performance

Historical Comparison
FRMI
GKOS

About FRMI Fermi Inc.

Fermi Inc is an energy and hyperscaler development company purpose-built for the AI era. Its Project Matador, a multi-gigawatt energy and data center development campus designed to support the accelerating needs of to-be-built AI infrastructure. Through its REIT structure, Fermi offers investors exposure to AI infrastructure growth and long-term, large-scale and reliable energy development in a tax-efficient public vehicle.

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: